Compare YSXT & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | XCUR |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.5M | 26.6M |
| IPO Year | 2024 | N/A |
| Metric | YSXT | XCUR |
|---|---|---|
| Price | $1.38 | $6.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 714.1K | 54.5K |
| Earning Date | 02-15-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $71,452,736.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.66 | ★ N/A |
| Revenue Growth | ★ 22.04 | N/A |
| 52 Week Low | $1.13 | $3.10 |
| 52 Week High | $9.96 | $15.91 |
| Indicator | YSXT | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 58.05 |
| Support Level | $1.37 | $6.05 |
| Resistance Level | $1.44 | $6.35 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 56.52 | 85.57 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.